INTRODUCTION
The eminent physiologist Claude Bernard wrote in his classic work entitled Experimental Science (8) . "Poisons can be employed as a means for the destruction of life or as agents for the treatment of the sick." He went on to explain how certain toxins and poisons were valuable tools for analyses of the most delicate phenomena of living structures. Although several toxic substances of plant and animal origin were used in medical practice during his time, in recent years a great multitude of poisonous substances from plants, animals, and microorganisms are now finding use in studies on animal physiology and some are used medicinally in humans.
In December 1989 the U.S. Food and Drug Administration licensed botulinum toxin type A as an orphan drug for the treatment of the human muscle disorders strabismus, hemifacial spasm, and blepharospasm in patients 12 years of age and older, by direct injection of the toxin into the hyperactive muscle. Botulinum toxin is also being used experimen-* Corresponding author.
tally for the treatment of a number of other dystonias and movement disorders (25, 98, 191) . The use of the toxin for human treatment came about over 20 years ago through the collaborative work of Alan B. Scott and E. J. Schantz . The treatment of neurological disorders with botulinum toxin type A has opened a new field of investigation on the application of the toxin to nerve and muscle tissue in the human body.
Various microbial neurotoxins are being used to understand the physiology of the nervous system and may have potential value in the treatment of certain types of muscular disorders through modification of nervous stimulation of muscle activity. Well-characterized microbial neurotoxins for this purpose include the neurotoxic proteins from Clostridium botulinum and Clostridium tetani and the low-molecular-weight neurotoxins saxitoxin and tetrodotoxin, from certain species of dinoflagellates and bacteria (Table 1) . These toxins affect muscular activity by their direct action on the nervous system; for example, botulinum and tetanus toxins affect activity by a presynaptic block of the release of neurotransmitters, and saxitoxin and tetrodotoxin do so by altering the action potential at the voltage-gated sodium channels of neurons. These toxins differ from many other (86) . The toxins are classified into seven serotypes, A through G, on the basis of their immunological properties. The botulinum neurotoxins comprise a family of pharmacologically similar toxins that block acetylcholine release from peripheral nerves and cause a flaccid paralysis. All of the serotypes of toxin can poison humans and other animals, but type A has caused the severest illness and many deaths from food-borne botulism and is the best-characterized botulinum toxin. Crystalline type A toxin is the serotype that is currently being used in therapeutic applications. The following sections describe the basic properties of botulinum toxin type A and the development of the toxin as a drug.
Investigations into the use of botulinum toxin type A for the treatment of hyperactive muscle disorders originated over 20 years ago through a fortunate set of circumstances and the ingenuity of Alan B. Scott, a surgeon at the SmithKettlewell Eye Research Institute in San Francisco. He contacted one of us (E.J.S.) regarding the availability of a toxic substance that might be injected into a hyperactive muscle and thus serve as an alternative to surgery for the treatment of strabismus, a condition in which the eyes are out of alignment. In my research on microbial toxins I had on hand highly purified crystalline type A botulinum toxin, produced by C. botulinum, and saxitoxin, the potent poison produced by the dinoflagellate Gonyaulax catenella. The mechanisms of action of these toxins had been known for many years (29, 33, 63, 103) , and their possible use in the treatment of a hyperactive muscle was apparent but had never been tested. No record of such use in animals or humans was available. Both botulinum toxin and saxitoxin cause flaccid paralysis of skeletal muscle as a result of action on the nervous system. Botulinum toxin type A appeared to be the toxin of choice for human treatment on the basis of animal studies and accidental cases of human food poisoning in which the paralytic action on survivors lasted for many weeks whereas recovery from saxitoxin poisoning took only a few days for survivors. We therefore began our collaboration on this work by using botulinum toxin experimentally on rhesus monkeys, in which Dr. Scott surgically produced a condition similar to strabismus. With the properly determined dose of botulinum toxin injected into the more active muscle, proper alignment of the eyes was achieved.
After 10 or more years of successful experiments on monkeys, the FDA granted Dr. Scott permission to treat strabismus in human volunteers. Strabismus in humans is a disorder of vision due to turning of one or both eyes from the normal position for binocular vision and is caused by hyperactivity of one or more muscles controlling eye position. This condition in humans usually is corrected by surgery, which involves cutting away a sufficient portion of the hyperactive muscle to allow the eye to assume its normal position. Successful human treatment with the toxin involved injecting measured amounts of the toxin, under carefully controlled conditions using electromyography, directly into the hyperactive muscle pulling the eye out of alignment. Injection of botulinum toxin weakened the overactive muscle, enabling compensation by the weaker one and resulting in permanent eye alignment after a period of temporary paralysis (192) . The clinical work was first reported by Scott in the 1980s (188, 189) , and the properties of the toxin in relation to its use in medical treatment was reported by Schantz and Scott in 1981 (180) .
Special considerations on the preparation and maintenance of botulinum toxin type A for human treatment. Although the original toxin on hand and that prepared for the monkeys was sufficient, the toxin to be used for the human trials had to be prepared under more specific conditions that would, from best judgment, meet approval by the FDA. Botulinum toxin is the first microbial protein to be used via injection for the treatment of human disease. There was no precedent for the use of a microbial toxin in this manner, and protocols for this work had to be implemented. The important considerations regarding the toxin were its purity and dose on injection. The production by culturing and the purification had to be carried out so that the toxin was not exposed to any substance that might contaminate the final product in trace amounts and cause undue reactions in the patient. These restrictions required culturing in simplified medium without the use of animal meat products and purification by procedures not involving synthetic solvents or resins. Another concern was the problem of long-term stability of the toxin so that a supply was always available. Dilution of the toxin from milligram quantities to a solution containing nanograms per milliliter presented a problem because of the rapid loss of specific toxicity on such great dilution. Toxin can be diluted in pyrogen-free water or saline if used immediately for treatment, but stabilization of the toxin for longer periods requires the presence of another protein such as gelatin or albumin (173, 177) . Although the commercial botulinum type A product is prepared in the presence of human serum albumin, the use of human serum albumin presents potential problems in that certain stable viral agents carried through from donors could contaminate the toxin.
These and other concerns about the preparation and use of the toxin for human treatment are reviewed and discussed in the following sections.
Mechanisms of action of botulinum toxin. The primary (32, 207) for both the neurotoxin and the nontoxic proteins. The isoelectric point of the crystalline type A toxin is pH 5.6. Under slightly acidic conditions, pH 3.5 to 6.8, the neurotoxic component of 150,000 Mr is bound noncovalently to the nontoxic proteins in such a manner as to preserve or help stabilize the second and tertiary structures upon which toxicity is dependent. Under slightly alkaline conditions (>pH 7.1) and in the blood and tissues of animals and humans, the neurotoxin is released from the toxin complex. RNA is also associated with the toxin complex but has no known role in activity or stability.
The molecular weight of crystalline toxin was initially shown to be 900,000 Mr on analysis in the ultracentrifuge at pH 3.8 to 4.4 (161, 173, 181, 229) . Putnam et al. (161) showed that on electrophoresis, the crystalline toxin moved as a single substance with a molecular weight of 900,000. Lamanna et al. (115) discovered that purified type A toxin could be separated into nontoxic and toxic components, when they found that a nontoxic component precipitated erythrocytes leaving the toxin in solution. Wagman and Bateman (229) also showed that the toxin moved in the ultracentrifuge as a single substance with a sedimentation coefficient of 19S at pH 5.6, but at pH 7.3 the toxin component (neurotoxin) dissociated and moved as a much smaller molecule (7S). Later DasGupta and Boroff (46) showed that at alkaline pH the neurotoxin could be separated from the nontoxic proteins by column chromatography.
On diffusion in agar gel at pH 4.2 the crystalline toxin moves as a single substance with a coefficient (D) of ca. 2 x 10-7 cm2 s-' (161, 178) . However, at pH 7.3, near to the pH at which the neurotoxin and nontoxic components dissociate, the diffusion rate of the neurotoxin increased to ca. 8 x 10-7 cm2 s-, much higher than the rate expected for a globular protein molecule of 150,000 Mr (178) . Diffusion depends to a great extent on the shape of the molecule, and the toxin may take on a threadlike structure that would diffuse faster than a globular structure.
The biological activity (toxicity) of the toxin, like many other biologically active proteins, is due to the spatial or conformational structure of the neurotoxin molecule (173, 182) . The nontoxic proteins bound to the neurotoxin apparently play an important role in maintaining the toxic shape of the neurotoxin. Careful handling of purified toxin is therefore important for maintenance of stability. Botulinum toxin type A is readily denatured by heat at temperatures above 40°C, particularly at alkaline pH. Solutions of the toxin lose toxicity when bubbles form at the air/liquid interface causing stretching and pulling of the neurotoxin out of its toxic shape (173) . This denaturation also takes place in an atmosphere of nitrogen or carbon dioxide. Dilution to extremely low concentrations (nanograms per milliliter) also tends to decrease the stability of the neurotoxin, but this can be prevented by diluting with a buffered solution (at pH 6.8 or below) containing another protein such as gelatin and certain albumins such as bovine or human serum albumin. When the pH is raised above 7.3, the neurotoxin is liberated, which is very labile. Because of its lability the neurotoxin is not practical for medical applications. 
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Crystalline botulinum toxin type A was the first microbial protein of this complexity to be considered an injectable substance by the FDA, and it was necessary to set down specifications for toxin quality. The following properties of the crystalline toxin obtained from many batches were found to be of the highest-quality toxin and were used for evaluation of batch , which was used in initial studies in humans and later licensed by the FDA: (i) a maximum absorbance at 278 nm when dissolved in 0.05 M sodium phosphate buffer at pH 6.8, (ii) an A26J/A27 ratio of 0.6 or less, (iii) a specific toxicity for mice of 3 x 10 ± 20% MLD50 per mg, and (iv) an extinction coefficient (absorbancy) of 1.65 for 1 mg of toxin per ml in a 1-cm light path.
The purity of the crystalline toxin cannot be defined strictly in terms of percent purity because of small amounts of undefined material absorbing at 260 nm, most probably nucleic acid material, which associates with the toxin during culturing and is carried through the purification and crystallization procedures. This property is peculiar to certain crystalline proteins, in contrast to the crystallization of other simpler organic substances. We have based the quality of the toxin on obtaining as low anA260JA278 ratio as possible, near to 0.55. Toxin from the first crystallization has a ratio close to 0.6, and on the second crystallization it should be reduced to about 0.55, which is considered representative of highquality toxin. A third crystallization may reduce the ratio slightly but at a cost of yield, because only one-third to one-half of the toxin is recovered on each crystallization. Other crystalline proteins such as human and bovine serum albumins have absorbance ratios close to 0.5 (232) . If it is assumed that the absorbing material at 260 nm is nucleic acid with an extinction of 20 per mg (12 times that of the toxin), the proportion of nucleic acid in a preparation with a ratio of 0.6 would be less than 0.1%.
Another test of purity and consistency for each batch of type A toxin is the banding pattern on solution electrophoresis and gel electrophoresis with crystalline toxin and reduced crystalline toxin. At or below the isoelectric point of 5.6, the toxin moves as a single homogeneous substance, of 900,000 Mr, Toxin reduced with sulfhydryl reagents shows the distribution after electrophoresis of the nontoxic components along with the neurotoxin subunits of 100,000 and 50,000 Mr. Electrophoresis carried out on several batches of crystalline toxin showed that the toxin is judged very similar for each batch (101) .
The specific toxicity of a high-quality preparation of crystalline toxin should be 3 x 107 MLD50 (+20%) per mg.
The number of milligrams for this determination is based on theA278, using the extinction of 1.65 to convert to milligrams of toxin (A278/1.65 = milligrams of toxin [+3%] ) (207) . Because the immunological properties of type A toxin are independent of its toxic properties, the only means of evaluating the potency or acetylcholine-blocking power of the toxin is an animal assay (176) . The mouse assay for toxicity determination may vary depending on the species of mice, their condition, and the conditions under which the assay is carried out. To minimize the variability, it is recommended that the mouse assay be carried out on any preparation used for human treatment with the use of a reference standard of type A toxin as described by Schantz and Kautter (177) (177) , in which it retained toxicity for 1 to 2 years before a significant loss (20%) could be detected by mouse assay. The difficulty with storing the toxin in acetate buffer is that freezing causes complete detoxification and reliance on storage at 4°C without danger of freezing is not practical under certain circumstances. However, we have found that the most satisfactory method of storage is to leave the crystalline toxin at 4°C in the mother liquor of the second crystallization, in which toxicity was retained for 10 or more years. Retaining stability is important because it makes available a bulk supply of toxin to draw from over an extended period. When the FDA approved experimental trials on human volunteers, a large batch of crystalline toxin was prepared in November 1979 (designated 79-11) expressly for the human trials; 100 mg was supplied to Alan Scott and 50 mg was retained in storage at the Food Research Institute. This batch has been the sole source of botulinum toxin type A accepted by the FDA for human treatment and has been used by many physicians throughout the United States and some foreign countries. However, some loss in toxicity has occurred in batch 79-11, and we recommend that fresher batches of toxin periodically be prepared to avoid detrimental changes that may occur on aging. Crystalline type A toxin prepared in our laboratory does not appear to differ in potency or clinical efficacy from type A toxin prepared in England by using anion-exchange chromatography and RNase treatment (133, 222) . However, we do not recommend the use of methods of purification involving enzymes, various exchangers, or synthetic solvents because of the chance of contamination.
Preparation of the toxin for dispensing as a drug and compatible for injection into muscle required (i) dilution in a suitable medium for stability of toxicity, (ii) filtration for sterility, and (iii) drying. Diluting a solution of botulinum toxin type A from a concentration of 1 or 2 mg/ml to nanogram concentrations causes detoxification unless another protein is added for protection. Gelatin at 2 to 3 mg/ml is generally used at pH 6.2 in the standard procedure for the mouse assay for toxin in foods (177) . Bovine serum albumin has been used at 2 to 3 mg/ml in acetate buffer at pH 4.2 for good stability (177) , and human serum albumin was adopted for medical use. Filtration in the presence of additional protein can be carried out successfully to remove bacterial contamination without loss of toxicity. However, drying, which would have many advantages in long-term stability, under the conditions with human serum albumin at pH 7.3 resulted in a substantial loss (50 to 90%) of toxicity. This loss of toxicity is a very important consideration because of the possibility that the inactivated toxin will form a toxoid and immunize the patient against the toxin on continued use. Various methods of drying, particularly lyophilization, resulted in such losses. Experience with the toxin has proved that stability of toxicity is dependent on low pH (<7), but such low pHs are not compatible with injections into muscle tissue. A significant problem is the development of a medium and conditions to overcome the losses on drying, and research for this purpose is being carried out in our laboratory.
Therapeutic applications of botulinum toxin. Clinical studies have indicated that toxin injections can provide profound symptomatic relief for humans suffering from a wide variety of disorders characterized by involuntary movements of muscle groups (Table 2) , particularly those involved in focal or segmental dystonias (25, 64, 92, 127 (25, 98, 179, 191) .
mans" to describe children who had movement disorders such as twisted postures, bizarre walking with bending and twisting of the torso, and severe muscle spasms. Oppenheim pointed out that progression of symptoms often resulted in fixed postural deformities. Dystonia is currently defined as "a syndrome of sustained muscle contractions, frequently causing twisting and repetitive movements or abnormal postures" (64, 127) . Dystonia can affect all regions of the body (127) . Many patients with dystonias have been diagnosed as experiencing psychological stress and referred for psychological therapy (64), but were later found to suffer from specific neurological diseases (64, 127) . Adult onset of focal or segmental dystonias (which affect only one or a few muscle groups) are more common than generalized dystonias (64, 127) . A study in Minnesota estimated the prevalence of various dystonias to be 391 per million population (147) . Focal dystonias may spread and lead to generalized dystonias, in which several muscle groups are involved. Focal dystonias progressed to generalized conditions in nearly 60% of affected children (onset before age 13) and in about 3% of adults (onset after age 20) (127) .
Crystalline botulinum toxin has had great benefit in the treatment of involuntary muscle conditions, and injection of toxin is now considered the most effective treatment for a variety of focal dystonias (25, 98, 191) . On injection the toxin acts directly or indirectly to alleviate conditions that result from muscle hyperactivity. Direct paralysis of target muscles is desired for certain indications including blepharospasm, torticollis, and other focal dystonias. Depending on the syndrome, toxin injection generally relieves undesired muscle movement for a few months, after which the abnormal movement returns and repeated injections are required. Paralysis of certain muscle groups can also lead to secondary desired effects (191) . For instance, paralysis of a hyperactive muscle enables compensation by a weaker muscle, as in treatment of strabismus and certain limb muscle spasmodic disorders. In these conditions, the balancing of agonist and antagonistic muscle systems is the desired effect (191) .
Strabismus was the first syndrome for which botulinum toxin therapy was introduced as an alternative to surgery (188, 189, 192) . Botulinum toxin is usually injected into the recti muscles with a Teflon-coated needle and electromyographic guidance to ensure accurate placement in the muscle; this is usually an office procedure. The toxin evokes a temporary denervation and muscle weakening, allowing the globe to return to normal alignment. Although botulinum toxin will not replace conventional surgical treatment, it has proved to be a useful adjunct to surgery in certain cases (189, 191) .
Botulinum toxin is being used primarily for the correction of focal dystonias and other regional movement disorders. One syndrome approved for treatment is essential blepharospasm, in which persons suffer from involuntary eyelid closure. Blepharospasm is often accompanied by involuntary movements of head and neck muscles, a condition known as Meige syndrome (98) . Meige syndrome manifests as uncontrolled blinking (blepherospasm) plus involuntary facial grimacing, frowning, facial contortions, spasmodic speech, and neck pulling (spasmodic torticollis) (24, 25) . The age of onset of blepharospasm is often 50 to 70 years, and the syndrome may progress to other muscle regions. Injections of botulinum toxin type A into the orbicularis oculi muscle has given clinically significant benefit in 70 to 90% of more than 8,000 treatments (98) . In most patients, the latency period from injection to onset of improvement was 2 to 5 days and relief persisted for an average of 3.5 months. The average dose was ca. 20 U (191) . In some treatments, toxin diffused to neighboring muscles and caused temporary ptosis. Some patients have received repeated injections for 7 years or more, and no adverse long-term effects have been observed.
Hemifacial spasm is an often disfiguring syndrome characterized by involuntary movement of facial muscles controlled by the seventh facial nerve. Patients often find the movements disfiguring and socially and functionally incapacitating (25) . Treatments with neuroleptic medications have been entirely ineffective. Injection of botulinum toxin (generally 10 to 20 U) has relieved hemifacial spasm in more than 90% of the patients treated. Most patients experience relief for 3 to 4 months, after which repeated injections have provided long-term relief in most individuals.
Spasmodic torticollis (cervical dystonia) is a dystonia affecting neck muscles and causing the head to involuntarily deviate in any direction (25, 75, 98, 208 25, 98, 191 , and 218). These include writer's and musician's cramps, hand tremors, spasmodic dysphonia and other laryngeal dystonias, neurogenic bladder as a result of spinal cord injury, spasms of the rectal sphincter (anismus), limb muscle spasms following stroke, leg spasms from multiple sclerosis, and spasticity in children with cerebral palsy. Botulinum toxin could potentially benefit humans who suffer from a variety of other hyperkinetic movement and muscle tone disorders including tics, tremors, bruxism, and pain brought on by muscle spasms (25, 98, 99, 218) .
Although botulinum toxin is currently used for treatment of regional muscle groups, limited success has also been achieved with patients who suffer from hyperactivity of several muscle groups. Botulinum toxin has found limited use in tardive dyskinetic syndrome (221), a chorea marked by irregular dystonic movements and postures that can develop in mentally ill patients after treatment with neuroleptic medications. Some of these patients experience marked distress and suffer from disparate spasmodic disorders including repetitive blinking, backward arching of the head and trunk (retrocollis), rocking of the body, mouth grinding (bruxism), and involuntary voice sounds and grunting. In a pilot study, four patients were injected in diverse muscles and marked improvement was found in 2 weeks in all four individuals. Not all movement disorders in these patients improved, but several did including retrocollis, mouth control, and bruxism. Treatment of tardive dyskinetic syndrome by chemical denervation with botulinum toxin is complex because it involves different muscle groups. The strategy has been to focus toxin injection on the most involved muscle groups.
Generalized dystonias such as those observed in Parkinsonism present difficult problems for treatment because of the many muscles involved, but it is possible that if a proper method of administration could be worked out, these generalized conditions could be treated with toxin. One possible but untried route is the administration of low intravenous doses by which the toxin would spread regionally to many muscles.
Side effects of botulinum toxin. No adverse clinical effects of botulinum toxin have been found in patients who received low doses of botulinum toxin, e.g., .20 U. Single-fiber electromyography analysis has shown that injection of relatively large quantities of botulinum toxin (140 to 165 U) leads to toxin spread, weakening of distant muscles, and uncharacterized subclinical effects (116) .
The primary side effect associated with local injections of botulinum toxin is weakening and ptosis of nearby muscles. One of the most prevalent and disturbing side effects is dysphagia, or the inability to swallow, and several patients have experienced upper airway obstruction after treatment with relatively high doses (>150 U) of botulinum toxin (25, 208) . Dysphagia may be related to generalized weakness and inability to hold the head erect (75) or to weakening of muscles involved in swallowing. It may also be related to the dose and injection strategy used. To prevent dysphagia, Borodic et al. (23, 24) have recommended, on the basis of studies of toxin diffusion in tissues, the use of .100 U per treatment injected into several sites. Further research is needed to identify the lowest dose of toxin and sites of injections that will produce the desired control and prevent migration of toxin to neighboring muscle groups. Local side effects could be increased in patients who are being treated with drugs other than botulinum toxin that affect neuromuscular transmission (4) .
There is interest among physicians in developing methods to prevent the spread of toxin to neighboring muscles. Scott (190) (53, 56, 57, 155) . Duchen (56, 57) (6, 186) . Repeated sensitivity to tetanus toxin in humans has also been reported (34) .
Toxoid is commonly injected into laboratory workers to Antibody formation has been observed in a small number of patients injected with botulinum toxin (98, 191) . To (168, 213, 215) , and type F has been the causative type in at least two outbreaks of food poisoning (78) . Symptoms and severity of botulism differ depending on the serotype and amount of toxin ingested, suggesting possible differences in the mechanisms of intoxication (215) . Clinical observations have indicated that type A food-borne botulism is often more severe and associated with higher mortality than botulism from other types (37, 52, 95) . A rapid onset of neurologic signs indicates a more severe episode of the disease (38) . Benign forms of botulism in which the course of the illness is milder and longer lasting have also been reported, particularly for type B (43, 100, 109, 209) .
Botulism in humans generally manifests as a rapidly progressive symmetrical neuromuscular paralysis. Patients with botulism generally stay mentally alert during the poisoning unless anoxia sets in (108) . Sudden respiratory or cardiac arrests and airway obstruction, leading to death, can occur (109) . Cardiac effects of botulinum toxin in animals and in humans have been reported (114, 215) . Botulinum toxin most often initially affects eye muscles supplied by susceptible cranial nerves, and the first signs of botulism are often blurred and double vision (215) . As the paralysis progresses and peripheral nerves are affected, signs such as dry mouth, difficulty in swallowing, weakness in head and neck movements, and difficulty in breathing become apparent. In type A and B botulism, loss of musculature control manifests as ptosis and drooping of eye muscles, hypoactive gag reflex, and weakness in upper and lower extremities (95) . Atypical symptoms including asymmetric or late-onset of neurologic signs, paresthesia, nystagmus, ataxia, and sensory abnormalities are not uncommon (31, 95, 215) . Ingested botulinum toxin can paralyze all muscles of the body. Symptoms of botulism sometimes last for months, and recovery requires renervation by new nerve terminal axons and end plates. Weakness and fatigability may persist for 1 to 2 years (215) . Recovery in adults is generally complete (38) , but there are reports of central nervous system involvement in infant botulism (lOOa).
Since botulism is rarely encountered, it can be difficult to diagnose rapidly. Electromyography is useful for detection of decreased amplitude of muscle action potential in weakened muscle (215) , and since conduction along the nerve axons is not altered by botulinum toxin, the proximal motor nerve conduction rates and distal latencies are normal (42) . Botulism is confirmed by the demonstration of botulinum toxin in the patient's serum or stool or in suspect food by mouse assay and neutralization with type-specific antitoxin (52) . Botulinum toxin has been found more often in the serum of patients with type E or B botulism than with type A, possibly because of the greater affinity of type A toxin for tissue acceptors.
The actual dose of botulinum toxin to cause food-borne intoxication in humans is debatable and depends on the individual, the source and type of toxin, and the amount ingested. Accidental cases of human botulism from toxincontaminated food showed symptoms of botulism and occasionally death from as little as 0.1 to 1 ,ug (100 to 1,000 ng or 3,000 to 30,000 MLD50s) (134, 140, 183) , but results were quite variable, probably because of individual variation in the amount absorbed and the stability of the toxin in the gut. More data on toxicity is available for lower animals and monkeys. The lethal dose of crystalline toxin type A in mice was 1.2 to 2.5 ng (0.03 to 0.07 U)/kg (76, 80) and was 0.5 to 0.6 ng/kg for guinea pigs and rabbits (76) . Scott and Suzuki (193) determined that the intramuscular LD50 for juvenile monkeys (Macaca fascicularis) was ca. 39 U/kg (ca. 1.25 ng/kg) of body weight. Herrero et al. (91) reported a similar lethal dose of 40 U/kg by intravenous injection in Macaca rhesus. In Gill's table of lethal amounts of bacterial toxins, he reported botulinum toxin to be the most potent toxin known for primates, the lethal quantity of type A toxin being 0.5 to 0.7 ng/kg of body weight for monkeys and ca. 1 ng (30 U)/kg for humans (76) . Larger quantities of types C1, D, and E may be required to cause death in monkeys, whereas less type B is required (76) . No data on intravenous toxicity are available for humans for botulinum toxins, but humans are probably as sensitive as guinea pigs and would be expected to be about as sensitive as monkeys.
Toxin production by the various serotypes of C. botulinum. Use of the various types of botulinum toxin in medicine will require a plentiful source of the toxins. The production of type A toxin under controlled conditions by the Hall strain, MICROBIOL. REV.
on October 16, 2017 by guest http://mmbr.asm.org/ Downloaded from as used for the preparation of toxin for human treatment, gives a uniform crystalline toxin in high yields. The toxin complexes of the other types have also been obtained by culturing and purification and could be useful clinically. However, the strain, medium composition, and culture conditions affect the yields and structures of the botulinum toxins.
To obtain the greatest quantity and highest quality of toxin, it is essential to maintain strains of C. botulinum that consistently produce high levels of toxin. However, the bacterium has a frustrating tendency under laboratory conditions to gradually lose its ability to produce high levels of toxin. Lewis and Hill (118) reported that the Hall strain made decreasing quantities of toxin on successive subcultures. Huhtanen (96) also reported that strains of type A and B toxins frequently become nontoxigenic during culture. A more complete understanding of the physiological and genetic factors that control toxin production will be Valuable for the development of other types.
The highest levels of toxin in group I C. botulinum (proteolytic strains of types A, B, and F) are generally produced in cell populations that undergo rapid autolysis and do not sporulate (21, 27) , although Siegel and Metzger (198) obtained titers of 6.3 x 105 U with the Hall strain in a fermentor without appreciable cell lysis. Toxin formation is poor during sporulation, and spores contain only small quantities of toxin (ca. 1% of that found in cytoplasm) (58, 77) . Takumi et al. (216) reported the isolation of nontoxigenic variants of C. botulinum type A that had enhanced sporulation. The strain used for production of type A, the Hall strain, sporulates very poorly. Therefore, encouraging vegetative growth and autolysis and discouraging spore formation may be important for obtaining good yields of toxin.
Toxin formation is controlled by nutrition in group I and II C. botulinum (119, 152) . Arginine delayed autolysis, affected sporulation, and repressed toxin formation in group I C. botulinum (28, 154) . Toxin formation was repressed about 10,000-fold in group I, including the Hall A and Okra B strains, when abundant arginine was available in the medium (152), probably owing to nitrogen repression of toxin gene expression. Protease was also decreased by arginine in group I C. botulinum. In group II C. botulinum (nonproteolytic strains of serotypes B, E, and F), tryptophan availability repressed toxin formation, probably also in response to nitrogen sufficiency (119) . These results indicate that fermentation conditions and mutant strains could be developed for improved toxin production.
Significance of complexes on toxin quality. The strain and culturing conditions also affect the quality of toxin that is produced. Schantz and Spero (181) found that botulinum toxins of the different serotypes occur in spent cultures as large protein complexes. In the ultracentrifuge the sedimentation coefficients for the complexes were 19S for type A, 16S for type B, and 13S for types C, D, E, and F. Sugii and Sakaguchi (211) showed that high-molecular-weight toxin complexes occur naturally in foods. It is now known that each of the types of botulinum toxin produced in food or in culture are conjugated proteins ranging in molecular weight from 300,000 to 900,000, comprising a molecule made up of one or two neurotoxic units of about 150,000 Mr noncovalently conjugated to nontoxic proteins (168, 181, 213) .
The formation of toxin complexes is very important for use of the toxins in medicine because the nontoxic proteins play an important role in maintaining the stability of the neurotoxic units. Isolated neurotoxic units were poorly toxic to mice when administered orally (169, 170, 210) . Peroral toxicity increased with incremental association of the neurotoxins with the protective proteins (150, [168] [169] [170] 210) . The larger (19S and 16S) complexes of botulinum toxin types A and B were more toxic by the oral route and more resistant to acid and pepsin than were the smaller complexes. The isolated neurotoxins were rapidly inactivated by these conditions. Variations in the toxigenicities of different strains also probably depend on differences in the structures of the complexes. Ohishi (150) found that the oral toxicities differed considerably for the toxins of certain type A and B strains of C. botulinum. Of five B strains, Okra B produced the most potent toxin by oral challenge in mice. The 16S complex of the toxin was 700 times more potent than the 16S molecule from strain NH-2. A hybrid composed of the neurotoxin from NH-2 and the nontoxic components from Okra increased the oral toxicity close to that of the native Okra toxin, probably by protection of the neurotoxin in the gastric and intestinal tracts.
The size of the complex formed in types A, B, E, and F depends on the medium for bacterial growth. It has been known for years that some foods such as vegetables have high botulinogenic properties (134, 212) . Sugii and Sakaguchi (212) showed that type A and B C. botulinum produced the stable 19S and 16S high-molecular-weight complexes in vegetables, whereas they produced the less stable 12S complex in tuna and pork. Nonconjugated neurotoxin was not found in any of the food substrates. They found that addition of iron or manganese to the growth medium resulted in a higher concentration of small toxin complexes (12S and 16S) in type A C. botulinum, suggesting an influence of metals on the size and stability of the complexes.
Biochemical and genetic properties of the neurotoxin component. The biochemistry of purified botulinum neurotoxins, particularly type A toxin, has been studied in considerable detail, and authoritative reviews are available (45, 81, 213) . Neurotoxins have been purified for all serotypes except for type G; the type G toxin has been purified to a protein complex of high toxicity, but further purification resulted in substantial loss of toxicity (126, 146) . Within a given type of toxin and strain of producing bacterium, there may be considerable heterogeneity in molecular structure and antigenicity, giving a mosaic structure (139) . The (45) and possibly a metal component (10, 11) . The H and L chains of the neurotoxins can be separated by chromatography after treatment with dithiothreitol and urea (171) . The isolated chains are not toxic by themselves but can be recombined under carefully controlled conditions to obtain active toxin (110, 123, 214, 230) .
Recently a chimeric toxin which retained considerable activity was prepared between the L chain of tetanus toxin and the H chain of botulinum toxin type A (230) . Chimeric toxins composed of defined fragments, e.g., the H chain from botulinum toxin and the L chain from ricin, could be VOL. 56, 1992 on October 16, 2017 by guest http://mmbr.asm.org/ Downloaded from valuable in medicine, but much work needs to be done on their formation and clinical testing.
During proteolytic cleavage the neurotoxins undergo a molecular change in shape that increases toxicity (48). The nicking region was recently reported to contain multiple target sites susceptible to more than one protease (45, 47) . DasGupta and Dekleva have proposed that two peptide bonds in a short region are cleaved at different rates during maturation of type A toxin and that 10 amino acids are excised (45, 47) . The control of proteolysis to increase stability could be useful in the preparation of the toxins for medicine, as has been achieved with tetanus toxin, and to obtain defined fragments for construction of toxins with desired properties.
The presence of metals in neurotoxins may affect their stability. Bhattacharyya and Sugiyama (10, 11) reported that chelators for iron and manganese inactivated purified type A botulinum toxin and tetanus toxin. Analysis of purified botulinum neurotoxin for metal content by neutron activation indicated that one atom of iron was present for each toxin molecule. It was suggested that metals may be involved in linkage of the H and L chains of botulinum and tetanus neurotoxins (10, 11). Kindler and Mager (107) found that metal availability in the culture medium affected the formation of toxin. Culturing C. botulinum in a medium containing EDTA did not inhibit growth but completely suppressed toxin formation. The biological activity of botulinum toxin may depend on a transition metal component, possibly Fe. The presence of metals could be important in maintenance of activity and protection from oxidation during drying and for long-term stability.
Recent genetic advances have increased our understanding of the structure and expression of the botulinum toxins. The genes coding for botulinum neurotoxin types A, B, and E are present in one copy on the chromosome in representative strains (14, 219) . Genomic libraries of C. botulinum type A chromosomal DNA (strain 62A or NCTC 2916) were prepared on plasmids and transformed into Escherichia coli. For safety reasons, separate subfragments that were 2 kb or less in size and did not encode the entire neurotoxin gene were cloned. Open reading frames which encoded a sequence corresponding to a polypeptide of 1,296 amino acid residues, 149 botulinum, AUG and UAA were translational initiation and termination codons, respectively, and strong bias was found for Arg and Ser codons. Binz et al. (14) found that the A+T content in the 5'-noncoding region of the type A and type E toxin genes was 80.4 and 80.3%, respectively, higher than in the coding regions, where 73.6 and 72.1% A+T were found. Examination of the upstream region indicated that transcription started 118 to 127 nucleotides upstream from the translation initiation site (14) . Regions of dyad symmetry were demonstrated in the 3' noncoding region that may be involved in regulation of transcription. Binz et al. (14) (61) . Cys-454 is the sole Cys residue in the N-terminal region of the H chain and is probably involved in disulfide bridging of the L and H chains. Cys-430 is also located at an identical position in botulinum and tetanus toxin L chains. Sequence analysis of botulinum type A toxin indicated that the H chain of type A neurotoxin had six histidine residues arranged in a motif which the authors suggested could be involved in the biological action of the toxin, possibly penetration through the nerve membrane. The deduced amino acid sequences of botulinum toxins had about 33% homology to tetanus toxin, and the H chains showed higher homologies than the L chains (14, 219) . No homologies were detected to other proteins including ADP-ribosylating clostridial toxins.
The DNA sequences have also recently been obtained for other botulinum toxins including type D, C1, and E neurotoxins and the C3 ADP-ribosyltranferase (13, 71, 72, 87, 105, 106, 157) . Highly homologous regions were detected among the various neurotoxin gene sequences and tetanus toxin gene. The C3 gene was found to be unrelated to C1 and D neurotoxin genes.
Structure and properties of nontoxic proteins of the toxin complex. Relatively little is known concerning the biochemistry and genetics of the nontoxic proteins associated with neurotoxin in toxin complexes. The type A complex contains at least two nontoxic proteins, one of which has hemagglutinating properties (115) . Strains of C. botulinum that do not produce hemagglutinin have been isolated, and these form smaller complexes (12S and 16S) than are normally found (19S) (111, 135, 211) . The in vitro addition of hemagglutinin to the 12S complex results in formation of a 19S complex with increased stability (111) . Binding of the hemagglutinin was inhibited by a heat-stable, dialyzable substance that has not been isolated (211) .
DasGupta (44) reported that the hemagglutinins of type A and B toxins were constructed through aggregation of two small units of about 15,000 and 20,000 Mr. Recently, Somers and DasGupta (204) Toxin types A and E, type B, and type F apparently bind to distinct high-affinity acceptor regions with similar affinities (KD 10-9 to 10-10 nM) in synaptosomes and at murine neuromuscular junctions (20, 45, 62, 110, 128, 228, 233) . Binding may occur in regions composed of sialosyl residues and protein (184) and may first involve low-affinity association of the H chain followed by high-affinity attachment. In addition to binding to different acceptor regions on the nerve surface, botulinum toxin types A and B have been reported to affect neurotransmitter release differently (74, 137) . Electrophysiological studies have shown that type A affects asynchronous neurotransmitter release, whereas type B does not (137) . Furthermore, an increase in the intracellular Ca' concentration by ionophore treatment reverses inhibition by type A but not type B in synaptosome preparations (5), and aminopyridine more readily reverses type A than type B inhibition at the myoneural junction (74) .
Both the H and L chains of the neurotoxin may be required for poisoning in invertebrate systems (123, 158) . In mammalian peripheral motor nerve terminals, the L chain alone is active after it is internalized (15, 49 ). The precise mechanism of blockade by the L chain is unknown, but it must affect a general and important component of the secretory machinery in various classes of neurons. Botulinum toxin blocks the release of several classes of neurotransmitters at central and peripheral neurons (15, 120) . Recently, it has been proposed that the L chain may act at an intracellular membranous or cytoskeletal site to inhibit neurotransmitter release (5, 120). Because of the extraordinary toxicity of botulinum toxin, it is likely that it has enzymatic activity and acts catalytically or triggers a cascade of events that decrease neurotransmitter release. The intracellular substrate of botulinum toxin remains an elusive grail that is being pursued by several laboratories.
An objective in treatment of hyperactive muscles is to prevent possible systemic reactions which could result from spread of toxin through the blood. Antibodies could be used therapeutically by application to the injection site to help limit the diffusion of toxin and alleviate side effects such as ptosis (190) , or it may also be possible to add the nontoxic H chain after toxin injection to block toxin binding to neighboring nerves. The most desirable approach to avoid spread would be to confine the paralyzing action within the presynaptic nerve. An interesting recent development is the finding that stabilized mRNA (3' (195) reported that injection of 1 to 20 U of crystalline type A botulinum toxin into the lower hindlimb of the rat produced a paralysis that lasted for several days. In contrast, injection of more than 1,200 U of type B neurotoxin was required to produce paralysis. The duration of paralysis was compared after injection of 20 U of type A or 5,000 U of type B toxin. Type A toxin caused paralysis for up to 7 days after injection, whereas type B toxin caused paralysis for only 3 days and twitching became evident at 5 to 7 days. It was also reported (104, 194) that pure type A neurotoxin was much more effective than type E or F neurotoxin in eliciting lasting paralysis in the lower hindlimb of rats.
Tetanus Toxin
Tetanus toxin, like botulinum toxin, is produced by an anaerobic sporeforming rod that has a similar morphology to C. botulinum (86) . Unlike botulinum toxin, tetanus toxin can enter into the central nervous system by retrograde intraaxonal transport through motor nerves (17, 81, 132) . It causes uncontrolled spasms of voluntary muscles by blocking the release of inhibitory transmitters including -y-aminobutyric acid and glycine (132) . Tetanus toxin also has significant activity in decreasing acetylcholine release in cholinergic peripheral nerves when injected locally (54) and could possibly be used as an adjunct to or independently VOL. 56, 1992 on October 16, 2017 by guest http://mmbr.asm.org/ Downloaded from from botulinum toxin for control of hyperactive muscles if the acquired immunity could be overridden. Tetanus toxin could also be used pharmacologically to transport substances to the central nervous system (17, 18) . The biochemistry and pharmacological activities have been recently reviewed (17, 81 (81, 88, 89) . The single-chain molecule is difficult to isolate (81) , and proteolytic modifications of the toxin have caused considerable difficulties in the accurate characterization of the molecule. Single-chain toxin can be prepared from washed extracted bacterial cells (88, 162) and by inclusion of protease inhibitors and use of specific purification procedures (7, 165, 231) . Purified preparations containing protease inhibitor can be stored for 4 to 6 weeks without proteolytic modifications and loss of toxicity (165) .
Conversion of tetanus toxin to the nicked form increases toxicity (7, 81) . C. tetani forms proteases that produce nicking in culture (231) , but many other endoproteases will also activate the toxin (2) . Three regions in the molecule are particularly susceptible to nicking (81, 129) . Mild trypsin treatment of intracellular single-chain toxin yields two chains of about 95,000 and 50,000 Mr. The modified tetanus molecule is strongly held together by noncovalent bonds, and reduction of disulfide does not result in separation of the chains. Strong denaturants such as urea or SDS (81, 166) or purification techniques such as isoelectric focusing (2, 231) are required to dissociate the chains.
The H chain of tetanus toxin possesses a particularly susceptible region that can be cleaved with proteases such as trypsin or papain, yielding two fragments (B and C) (2, 89).
The isolated H and L chains and fragments B and C are poorly toxic compared with intact tetanus toxin (2). AhnertHilger et al. (2) reported that the nicking sites contributing to toxicity are located within a region spanning no more than 17 amino acids, and the N and C termini are not altered during the modification. The separated chains were reconstituted to active toxin. By reconstitution experiments, the L chain was demonstrated to possess the paralyzing activity in isolated nerve-muscle preparations. The H chain is required for toxin entry into the nerve tissues and for axonal transport (2) .
Large-scale production of tetanus toxin. Tetanus toxin is produced in deep culture by methods similar to those described for botulinum toxin. J. Howard Mueller, Pauline Miller, and associates at Harvard Medical School developed the methods currently used for production of tetanus toxoid. They experienced much frustration in obtaining consistent quality and the high titers of toxin required for toxoid demand (121, (142) (143) (144) . They realized the importance of medium formulation in obtaining good-quality tetanus toxin, "If it were only possible to grow the tetanus organism on a medium containing only chemically defined substances of low molecular weight, it should become a relatively straightforward matter to study and control the factors involved in toxin production, and to obtain a uniform product free from any possible antigenic material other than the specific substance desired." (141) . An extensive study was carried out to identify factors controlling tetanus toxin formation (143) . On fractionation of components of the medium, the basis of good production was determined to be present in a pancreatic digest of casein. The key to good toxin production by C. tetani was later determined to be limitation of histidine (144) . Abundant free histidine drastically decreased toxin production, while its limitation strongly increased titers (144) . Since histidine is required for growth of C. tetani, it was necessary to find a method to limit the nutrient without stopping growth. Mueller and Miller found that providing histidinecontaining peptides (e.g., glycyl-histidine) or histidine esters (e.g., acetyl-histidine) stimulated toxin production. Latham et al. (117) developed a protein-free medium which is currently used for tetanus toxin production. Mueller and Miller also isolated a high-producing strain (the Harvard or Massachusetts strain) (142) that is still widely used by many laboratories.
Tetanus toxin synthesis was found to be repressed by the addition of excess amino acids to the medium (223) . Mellanby (131) reported that glutamate addition to the Mueller and Miller growth medium decreased toxin formation but shortened the time necessary for autolysis. The results indicate that nitrogen nutrition controls toxin regulation in C. tetani. It is interesting that excess nitrogen also represses botulinum toxin synthesis in C. botulinum (119, 152) . Careful adjustment of the levels of iron salts in the medium is also necessary for good tetanus toxin production (67, 142) . The mechanisms of nutritional regulation and its importance in the biology of C. tetani and C. botulinum have not been further studied to our knowledge.
Tetanus toxin, like botulinum toxin, is produced in highest quantities by nonsporulating cultures (85, 145) . Highly toxigenic cultures autolyzed thoroughly and did not form endospores during culture. During culture, tetanus toxin was present within the cell and was not released until cultures lysed (141, 162) . As with C. botulinum, it appears that toxin formation is associated with autolytic growth and inversely associated with sporulation (145, 153) . It would be of interest to determine whether specific transcription factors, e.g., sigma factors, regulate transcription of the toxin gene and whether these are preferentially expressed or activated in autolytic growth compared with sporulation.
Genetics of tetanus toxin. Tetanus toxin production has (68, 142) . Attempts were made early to correlate the toxigenicity with the presence of bacteriophage. Phages were induced in C. tetani by treatment with mitomycin C, but induction did not affect toxin production (159, 160) . Nontoxigenic mutants were readily isolated at high frequency (0.8 to 3.2%) from the Harvard strain A47 by treatment with various mutagenic agents including N-methyl-N'-nitro-N-nitrosoguanidine, UV light, and rifampin (85) . Hara et al. (85) found that cured, nontoxigenic strains still carried phages and proposed that plasmids could be involved in toxigenesis. Laird et al. (112) showed that toxigenicity was associated with the presence of a single large plasmid in 21 strains of diverse origin. Nontoxigenic derivatives were isolated, and each strain lost its plasmid. Two naturally occurring nontoxigenic strains were examined, and one was free of plasmids while the other contained a single large plasmid (112) . The strains derived from the Harvard strain all contain a plasmid of 49 kb, which had identical restriction nuclease digestion patterns (112 Tetanus toxin also can act peripherally, causing a flaccid paralysis in the manner that characterizes botulinum toxin (54) . H chains of both botulinum and tetanus toxins form channels in lipid bilayers (94) . The H2 fragment of the H chain of tetanus toxin was found to antagonize the action of botulinum toxin in phrenic nerve-hemidiaphragm preparations (201, 202) . Tetanus toxin is about 2,000 times more toxic at central inhibitory nerves than at peripheral synapses (12, 54) and is about 1,000 times less toxic than botulinum toxin type A at the myoneural junction (82). Dreyer and Schmitt (55) proposed that tetanus toxin and botulinum toxin type A act at different sites in nerve inhibition of transmitter release. Botulinum toxins type B (74, 195) , D (54), and F (104), but not A (74), appeared to act in a similar manner to tetanus toxin in affecting transmitter release from the myoneural junction. The combination of botulinum and tetanus toxins or the construction of chimeras could potentially be used to control neurological disorders.
MICROBIAL NEUROTOXINS THAT ALTER VOLTAGE-GATED SODIUM CHANNELS
Other microbial neurotoxins impair muscle activity in a way different from botulinum and tetanus toxins by their effect on the action potential at the sodium channel of a nerve axon. Saxitoxin and tetrodotoxin are two classical examples of microbial neurotoxins that block or close the passage of sodium ions through the channel. Toxins produced by other dinoflagellates also produce changes in the action potential at the sodium channel and are briefly described below.
Saxitoxin is a potent rapidly acting neurotoxin produced by the marine dinoflagellate Gonyaulax catenella (206) and some bacteria (102, 122) . Like botulinum toxin, it was first observed as a food-borne toxin, causing food poisoning that occurred only at certain times from consumption of mussels, clams, and some other shellfish that are plankton feeders. Consumption of toxic shellfish results in symptoms described as numbness of the lips and fingertips within a few minutes followed by a progressive paralysis of the arms and legs along with the development of labored breathing and asphyxia. Death may occur within 2 to 24 h, depending upon the dose, from respiratory paralysis. After survival for 24 h the prognosis is good, and no lasting effects of the toxin have been observed. The oral dose that causes death from accidental consumption of toxic shellfish by humans is 1 to 4 mg (5,000 to 20,000 mouse units) depending upon the age and physical condition of the patient. A mouse unit (MU) is defined as the minimum amount needed to cause the death of an 18-to 22-g white mouse in 15 min, which is usually the maximum time in which death will occur (174, 205) .
Saxitoxin was first purified and crystallized by Schantz et al. (172, 179) , and its structure was determined by X-ray crystallography by Jon Clardy (175) . Purified saxitoxin is a very hygroscopic water-soluble toxin and is described chemically as a tetrahydropurine base with pKas at 8.5 and 11.5. It has a molecular weight of 299 as the free base. It has no UV absorption above 210 nm. As the dihydrochloride salt it is a white solid that is stable in acidic solution but loses activity above pH 7. The paralyzing action of saxitoxin or its binding at the receptor of the sodium channel depends upon the presence of a hydrated ketone group in a particular position in the molecule. Reduction of this group to the alcohol results in the loss of over 99% of the binding and paralyzing activity.
The neurotoxic action of saxitoxin is due to its specific binding, even at extremely low concentrations (10-9 M), at the sodium channel of excitable membranes and preventing the passage of sodium ions through the sodium channel, thus blocking an impulse. The action or binding is concentration dependent, and binding is reversible. Controlled application of the toxin has been suggested as a possible local anesthetic. The effective dose in animals is relatively close to the lethal dose, as indicated by the steepness of the response curve, and pharmaceutical companies have not pursued its use in humans. However, when saxitoxin is mixed in small amounts with many classes of anesthetics, the effectiveness of the anesthetic action is greatly extended (1) . The addition of 1 ,ug of saxitoxin to a 1% solution of a typical anesthetic (1 part in 10,000) such as procaine increased the time of effective action two-to threefold (1). The result is not an additive one (1) . The addition of saxitoxin to procaine as well as to other anesthetic compounds will also reduce the dose required to obtain a desired effect. The reason for this unusual action of saxitoxin with anesthetic compounds has not been fully explained, but the molecule must play an important part in nervous function in the presence of other substances that act on the nervous system. Saxitoxin and tetrodotoxin have been important in the establishment and characterization of the sodium channel in myelinated and unmyelinated nerve membranes (90, 93, 102, 163, 164) and for the study of related diseases such as multiple sclerosis.
Another species of dinoflagellates, Gonyaulax tamarensis var. excavata, produces saxitoxin substituted with sulfate and sulfonic acid groups (63, 102) . These substituted toxins have a lower specific toxicity or binding at the sodium channel than saxitoxin does, but they should not be overlooked for possible medical use.
Tetrodotoxin was originally found in the roe, ovaries, and liver of the puffer or globe fish (Tetfaodontidae) caught in the western Pacific ocean and was at first believed to be exclusively produced by this fish. More recently it has also been found in various other animals including the California newt, octopus, and frog (234) and in marine bacteria (51, 199, 220, 235) . Dinoflagellates have been proposed as the original source of the toxin in puffer fish, which acquire it through the food chain (234) .
The action of tetrodotoxin is like that of saxitoxin in blocking the sodium channel of excitable membranes of nerve and muscle tissue. In fact, it has been shown that both tetrodotoxin and saxitoxin block the inward current of sodium ions at equally low concentrations of 10-7 to 10-9 M and occupy the same receptor sites at the sodium channel (63, 103) . The basic structure of tetrodotoxin is markedly different from that of saxitoxin and is chemically described as aminoperhydroquanizoline, with a molecular weight of 319. Although the two toxins are basically different in structure, they may be similarly classified as heterocyclic guanidines because of the guanidium group common to each toxin. Kao and Nishiyama (103) first proposed that the guanidinium moieties of each toxin might enter at the sodium channel like guanidine and that the bulk of the remaining part of the molecule prevented the passage of the sodium ion.
Although this hypothesis may be consistent with many aspects of the action of the toxins, it appears that the chemical makeup of the molecule as well as the guanidine group is involved. The reduction of the hydrated ketone group to an alcohol in the saxitoxin molecule completely destroys its effectiveness as a blocker of the sodium channel, and changes in the structure of tetrodotoxin also affect its bonding (102) . The purpose here is to point out in a general way the nature of the two toxins and how they might affect the action of other toxins used for treatment of hyperactive muscles. The fact that saxitoxin enhances the action of local anesthetics has raised some thoughts on the relation of one toxin to another on an excitable membrane. Reviews by Catterall (36) , Kao et al. (102, 103) , and Borison et al. (22) give detailed descriptions of the action of the microbial neurotoxins saxitoxin and tetrodotoxin (binding site 1 at the sodium channel) and compare them with neurotoxins from other nonmicrobial sources that affect the sodium channel, such as veratridine, aconitine, batrachotoxin, grayanotoxin, and the low-molecular-weight basic polypeptide toxins isolated from scorpion venoms, fish-hunting cone snails, and sea anemone nematocysts (binding site 2 at the sodium channel). These reviews point out the various mechanisms by which toxins might affect the nervous system via action at the sodium channel. From the proposed action it seems reasonable to assume that there may be value in the use of combined toxins for control of nervous activity.
It is quite interesting that the action potential at the sodium channel is also affected by certain substances, such as guanidine and 3,4-diaminopurine, that reverse or bypass the blocking action of botulinum toxin. Although these substances are not particularly good antidotes for the toxin, their action indicates a relationship between the action potential at the sodium channel and the liberation of a neurotransmitter at the nerve ending. One might assume, therefore, that substances such as saxitoxin, tetrodotoxin, or others that alter the action potential at the sodium channel should warrant further investigation for possible medical application. Guanidine, an effective substitute for sodium in action potential generation in excitable membranes (93) , is also reported to relieve symptoms of botulism (39) , suggesting that there may be interactions of toxins at the myoneural junction, a field that warrants further study. Besides the microbial neurotoxins described thus far, there are other, less well understood microbial neurotoxins that may be found valuable for nerve and muscle control mainly because of their action at the sodium channel. Gymnodinium breve, a marine dinoflagellate responsible for the Florida red tides and the tremendous fish kills in that area, produces several toxins, two of which are neurotoxins designated brevitoxins A and B, that have some action at the sodium channel (22) . These two toxins are lipid-soluble polyethers with a molecular weight around 900. Brevetoxin A has an indirect action on the sodium channel in that it enhances channel activity in the presence of toxins that bind to receptor site 2 at the sodium channel, but not to receptor site 1. Gambierdiscus toxicus, a tropical reef-dwelling dinoflagellate, produces several toxins, including one designated ciguatoxin, which opens voltage-dependent sodium channels in cell membranes (186) . This toxin is a lipid-soluble polyether with a molecular weight of 1112 and is concentrated as it is passed up the food chain to large predatory reef fish consumed by humans. The disease in humans affects both gastrointestinal and neurological systems. The neurological symptoms usually begin within 24 h and may last a month or more, indicating nerve blockage or damage requiring regeneration of nervous tissue. Afflicted persons experience circumoral paresthesias, paresthesias or paralysis of the extremities, and muscle pain.
Natural blooms of the freshwater blue-green alga (cyanobacterium) Aphanizomenon flos-aquae which occur periodically in lakes of the northern United States and certain provinces of Canada have caused poisoning of farm animals from drinking the water. This organism produces several toxins including saxitoxin and neosaxitoxin. Another species of this group, Anabena flos-aquae, produces a substance that affects acetylcholine receptors in muscle membranes (35, 97) . Some mycotoxins affect the nervous system in various ways. Slaframine, upon biological conversion to a quaternary amine, causes excessive salivation in farm animals and acts similarly to acetylcholine (30, 41) . These organisms and other microorganisms produce other neural toxins, but little is known of their action and importance in pharmacology and physiology. CONCLUSIONS Butulinum toxin type A has been found useful for the treatment of many hyperactive muscle disorders by intramuscular injection, and the FDA has licensed the toxin for treatment of strabismus, blepharospasm, and hemifacial spasm. It is the first microbial toxin to be used for human treatment. Because it is injected into humans, purity is of prime importance and, therefore, during the production by culturing and purification, it must not be exposed to any substances that might be carried in trace amounts to the crystalline toxin and cause undue reactions in the patient. Injection of the toxin into muscle tissue has opened a new field of investigation into the action of the toxin on muscle and nerve tissue and has been beneficial to many humans who suffer from dystonias.
Types of botulinum toxin other than type A toxin and perhaps tetanus toxin may be useful for human treatment if patients develop immunity to type A toxin. Saxitoxin stimulates and prolongs the action of local anesthetics, suggesting the use of combined toxins for human treatment. Some microbiological toxins are described for possible use alone or combined with botulinum toxin for medical treatment.
drugs and A23187 reveal differences in the inhibition of synaptosomal transmitter release by botulinum neurotoxins types A and B. J. Neurochem. 56:827-835.
